These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21936400)

  • 1. Combretastatin A4 phosphate induces programmed cell death in vascular endothelial cells.
    Ding X; Zhang Z; Li S; Wang A
    Oncol Res; 2011; 19(7):303-9. PubMed ID: 21936400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological and anti-vascular activity evaluation of ethoxy-erianin phosphate as a vascular disrupting agent.
    Yuan W; Su C; Yang X; Li Y; Cao Y; Liang X; Liu J
    J Cell Biochem; 2019 Oct; 120(10):16978-16989. PubMed ID: 31111562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling.
    Vincent L; Kermani P; Young LM; Cheng J; Zhang F; Shido K; Lam G; Bompais-Vincent H; Zhu Z; Hicklin DJ; Bohlen P; Chaplin DJ; May C; Rafii S
    J Clin Invest; 2005 Nov; 115(11):2992-3006. PubMed ID: 16224539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death.
    Petit I; Karajannis MA; Vincent L; Young L; Butler J; Hooper AT; Shido K; Steller H; Chaplin DJ; Feldman E; Rafii S
    Blood; 2008 Feb; 111(4):1951-61. PubMed ID: 18024794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcatheter Arterial Embolization Combined with Anti-vascular Agent Combretastatin A4 Phosphate Inhibits Growth and Vascularization of Liver Tumor in an Animal Model.
    Zhao H; Wu ZZ; Ren Q; Wu JJ; Wang Y; Feng JW; Rao M; Deng Q; Hu HY
    Curr Med Sci; 2022 Dec; 42(6):1240-1247. PubMed ID: 36462132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.
    Galbraith SM; Chaplin DJ; Lee F; Stratford MR; Locke RJ; Vojnovic B; Tozer GM
    Anticancer Res; 2001; 21(1A):93-102. PubMed ID: 11299795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).
    Siemann DW; Chaplin DJ; Walicke PA
    Expert Opin Investig Drugs; 2009 Feb; 18(2):189-97. PubMed ID: 19236265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors.
    Dziba JM; Marcinek R; Venkataraman G; Robinson JA; Ain KB
    Thyroid; 2002 Dec; 12(12):1063-70. PubMed ID: 12593719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sydnone Cycloaddition Route to Pyrazole-Based Analogs of Combretastatin A4.
    Brown AW; Fisher M; Tozer GM; Kanthou C; Harrity JP
    J Med Chem; 2016 Oct; 59(20):9473-9488. PubMed ID: 27690431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage.
    Nabha SM; Mohammad RM; Dandashi MH; Coupaye-Gerard B; Aboukameel A; Pettit GR; Al-Katib AM
    Clin Cancer Res; 2002 Aug; 8(8):2735-41. PubMed ID: 12171907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro antiproliferative and antiangiogenic effects of Flavin7.
    Mojzis J; Sarisský M; Pilátová M; Voharová V; Varinská L; Mojzisová G; Ostro A; Urdzík P; Dankovcik R; Mirossay L
    Physiol Res; 2008; 57(3):413-420. PubMed ID: 18597584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combretastatin A4 phosphate.
    West CM; Price P
    Anticancer Drugs; 2004 Mar; 15(3):179-87. PubMed ID: 15014350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with a vascular disrupting agent does not increase recruitment of indium labelled human endothelial outgrowth cells in an experimental tumour model.
    Bertelsen LB; Bohn AB; Shen YY; Falborg L; Stødkilde-Jørgensen H; Horsman MR
    BMC Cancer; 2014 Dec; 14():903. PubMed ID: 25466422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
    Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
    J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate.
    Lunt SJ; Akerman S; Hill SA; Fisher M; Wright VJ; Reyes-Aldasoro CC; Tozer GM; Kanthou C
    Int J Cancer; 2011 Oct; 129(8):1979-89. PubMed ID: 21154772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy.
    Nabha SM; Mohammad RM; Wall NR; Dutcher JA; Salkini BM; Pettit GR; Al-Katib AM
    Anticancer Drugs; 2001 Jan; 12(1):57-63. PubMed ID: 11272287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The vascular-disrupting agent, combretastatin-A4-phosphate, enhances neurogenic vasoconstriction in rat small arteries.
    Su J; Laursen BE; Eskildsen-Helmond Y; Horsman MR; Simonsen U
    Eur J Pharmacol; 2012 Nov; 695(1-3):104-11. PubMed ID: 22981665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inhibitory effect of tetrandrine on angiogenesis].
    Qian XP; Liu BR; Hu J; Li M; Hu WJ; Sun J; Yu LX
    Ai Zheng; 2008 Oct; 27(10):1050-5. PubMed ID: 18851784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic antiangiogenic activity of tetrandrine combined with Endostar on the human umbilical vein endothelial cell model.
    Qian X; Yan B; Zhou X; Xie L; Wei J; Li R; Yu L; Liu B
    Cancer Biother Radiopharm; 2013 Jun; 28(5):385-90. PubMed ID: 23682584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model.
    Yeung SC; She M; Yang H; Pan J; Sun L; Chaplin D
    J Clin Endocrinol Metab; 2007 Aug; 92(8):2902-9. PubMed ID: 17550961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.